Concord Medical to Restate 2024-2025 Financials After SEC Flags Loss of Control Over Key Subsidiary
CCM sits 17% above its 52-week low of $3.18 on light trading volume (0.1× avg).
Summary
Concord Medical announced its auditor resigned and that it will restate its 2024 and 2025 financial statements after the SEC determined the company lost control of its key subsidiary, Concord Healthcare Group, in 2024.
Key Events · Legal and Risk Events · CCM
-
Auditor Resignation and Replacement
Shandong Haoxin resigned as independent auditor on September 14, 2026; Guangdong Prouden CPAs GP was engaged on September 22, 2026, approved by the audit committee.
-
Non-Reliance on 2024-2025 Financials
The company concluded its audited consolidated financial statements for fiscal years ended December 31, 2024 and 2025 should no longer be relied upon and will be restated.
-
SEC-Required Deconsolidation of CHG
SEC staff determined the company lost controlling financial interest in Concord Healthcare Group when its voting interest fell below a majority in 2024, requiring deconsolidation under ASC 810.
-
Material Weakness in Accounting Resources
The company disclosed a material weakness related to lack of accounting staff and resources with appropriate knowledge of U.S. GAAP and SEC reporting and compliance.
Analysis · CCM · Industrial Applications And Services
Concord Medical disclosed that its auditor resigned and that it can no longer rely on its audited financial statements for fiscal years 2024 and 2025. The SEC staff concluded the company lost controlling financial interest in Concord Healthcare Group (CHG) when its voting interest fell below a majority in 2024, requiring deconsolidation under ASC 810. The company will restate both years to remove CHG from its consolidated results. This is a major accounting integrity event: the restatement will materially change reported revenue, assets, and liabilities, and the auditor change plus the disclosed material weakness in U.S. GAAP expertise compound the governance concerns. The company's prior auditor had already issued a going-concern explanatory paragraph, so the restatement adds further uncertainty about the reliability of historical financials.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.6% of the 317 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CCM was trading at $3.71 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $16.2M. The 52-week trading range was $3.18 to $6.98. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.